Cholestagel

Country: Unjoni Ewropea

Lingwa: Ingliż

Sors: EMA (European Medicines Agency)

Ixtrih issa

Ingredjent attiv:

colesevelam (as hydrochloride)

Disponibbli minn:

CHEPLAPHARM Arzneimittel GmbH

Kodiċi ATC:

C10AC04

INN (Isem Internazzjonali):

colesevelam

Grupp terapewtiku:

Lipid modifying agents

Żona terapewtika:

Hypercholesterolemia

Indikazzjonijiet terapewtiċi:

Cholestagel co-administered with a 3-hydroxy-3-methyl-glutaryl-coenzyme-A (HMG-CoA)-reductase inhibitor (statin) is indicated as adjunctive therapy to diet to provide an additive reduction in low-density-lipoprotein-cholesterol (LDL-C) levels in adult patients with primary hypercholesterolaemia who are not adequately controlled with a statin alone.Cholestagel as monotherapy is indicated as adjunctive therapy to diet for reduction of elevated total cholesterol and LDL-C in adult patients with primary hypercholesterolaemia, in whom a statin is considered inappropriate or is not well tolerated.Cholestagel can also be used in combination with ezetimibe, with or without a statin, in adult patients with primary hypercholesterolaemia, including patients with familial hypercholesterolaemia (see section 5.1).

Sommarju tal-prodott:

Revision: 23

L-istatus ta 'awtorizzazzjoni:

Authorised

Data ta 'l-awtorizzazzjoni:

2004-03-09

Fuljett ta 'informazzjoni

                                17
B. PACKAGE LEAFLET
18
PACKAGE LEAFLET: INFORMATION FOR THE USER
CHOLESTAGEL 625 MG FILM-COATED TABLETS
Colesevelam
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Cholestagel is and what it is used for
2.
What you need to know before you take Cholestagel
3.
How to take Cholestagel
4.
Possible side effects
5.
How to store Cholestagel
6.
Contents of the pack and other information
1.
WHAT CHOLESTAGEL IS AND WHAT IT IS USED FOR
Cholestagel contains the active substance colesevelam (as
hydrochloride). Taking Cholestagel helps to
lower the level of cholesterol in your blood. Your doctor should only
give you Cholestagel if a diet
low in fat and cholesterol did not work well enough on its own.
Cholestagel works in your intestinal system by binding bile acids
produced by your liver and carrying
the bile acids out of your body with your faeces. This prevents your
body from recycling the bile acids
from your intestines in the usual way. Without the recycling process,
your liver has to make additional
bile acids. Your liver uses cholesterol from your blood to do this,
which lowers the level of cholesterol
in your blood.
Cholestagel is prescribed to treat a condition known as primary
hypercholesterolaemia (when
cholesterol in the blood is elevated) in adults.
-
Cholestagel may be prescribed on its own in addition to a diet low in
fat and cholesterol when
treatment with a statin (a class of cholesterol-lowering medicines
that work in the liver) is
inappropriate or not well tolerated.
-
Cholestagel may be u
                                
                                Aqra d-dokument sħiħ
                                
                            

Karatteristiċi tal-prodott

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Cholestagel 625 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 625 mg colesevelam (as hydrochloride).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).
Off-white, capsule-shaped film-coated tablets imprinted with
“C625” on one side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Cholestagel co-administered with a
3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase
inhibitor (statin) is indicated as adjunctive therapy to diet to
provide an additive reduction in
low-density lipoprotein cholesterol (LDL-C) levels in adult patients
with primary
hypercholesterolaemia who are not adequately controlled with a statin
alone.
Cholestagel as monotherapy is indicated as adjunctive therapy to diet
for reduction of elevated
total-cholesterol and LDL-C in adult patients with primary
hypercholesterolaemia, in whom a statin is
considered inappropriate or is not well-tolerated.
Cholestagel can also be used in combination with ezetimibe, with or
without a statin, in adult patients
with primary hypercholesterolaemia, including patients with familial
hypercholesterolaemia (see
section 5.1).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Combination therapy _
The recommended dose of Cholestagel for combination with a statin with
or without ezetimibe is 4 to
6 tablets per day. The maximum recommended dose is 6 tablets per day
taken as 3 tablets twice per
day with meals or 6 tablets taken once per day with a meal. Clinical
trials have shown that Cholestagel
and statins can be co-administered or dosed apart, and that
Cholestagel and ezetimibe can be co-
administered or dosed apart.
_ _
_Monotherapy _
The recommended starting dose of Cholestagel is 6 tablets per day
taken as 3 tablets twice per day
with meals or 6 tablets once per day with a meal. The maximum
recommended dose is 7 tablets per
day.
During therapy, the cholesterol-lowering diet shoul
                                
                                Aqra d-dokument sħiħ
                                
                            

Dokumenti f'lingwi oħra

Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Bulgaru 25-05-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Bulgaru 25-05-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Spanjol 25-05-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Spanjol 25-05-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ċek 25-05-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ċek 25-05-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Daniż 25-05-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Daniż 25-05-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ġermaniż 25-05-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ġermaniż 25-05-2021
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ġermaniż 17-05-2010
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Estonjan 25-05-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Estonjan 25-05-2021
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Estonjan 17-05-2010
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Grieg 25-05-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Grieg 25-05-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Franċiż 25-05-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Franċiż 25-05-2021
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Franċiż 17-05-2010
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Taljan 25-05-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Taljan 25-05-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Latvjan 25-05-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Latvjan 25-05-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Litwanjan 25-05-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Litwanjan 25-05-2021
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Litwanjan 17-05-2010
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ungeriż 25-05-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ungeriż 25-05-2021
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ungeriż 17-05-2010
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Malti 25-05-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Malti 25-05-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Olandiż 25-05-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Olandiż 25-05-2021
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Olandiż 17-05-2010
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Pollakk 25-05-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Pollakk 25-05-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Portugiż 25-05-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Portugiż 25-05-2021
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Portugiż 17-05-2010
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Rumen 25-05-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Rumen 25-05-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Slovakk 25-05-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Slovakk 25-05-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Sloven 25-05-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Sloven 25-05-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Finlandiż 25-05-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Finlandiż 25-05-2021
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Finlandiż 17-05-2010
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Svediż 25-05-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Svediż 25-05-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Norveġiż 25-05-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Norveġiż 25-05-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Iżlandiż 25-05-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Iżlandiż 25-05-2021
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Kroat 25-05-2021
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Kroat 25-05-2021

Fittex twissijiet relatati ma 'dan il-prodott

Ara l-istorja tad-dokumenti